Table 6.
GMSC-based regenerative therapy for nerve regeneration.
| Cell Type | Scaffolds/other factors | Dose | Model | Refs | |
|---|---|---|---|---|---|
| GMSC-NC | AxoGuard nerve conduits | 0.5×106 cells/rat | Facial nerve defect | Rat | Zhang et al. (119) |
| GMSC | 3D spheroid, 3D bioprinting | Facial nerve defect | Rat | Zhang et al. (120) | |
| GMSC-NPC | GelFoam | 2×105 cells/rat | Sciatic nerve crush-injury | Rat | Zhang et al. (124) |
| GMSC-EVs | GelFoam | 40µg/mice | Sciatic nerve crush-injury | Mice | Mao et al. (125) |
| GMSC-EVs | Chitin conduits | 10 μg/rat | Sciatic nerve segmental defect, 10 mm gap | Rat | Rao et al. (126) |
| GMSC | Liposome enriched with moringin (MOR) treatment | 1×106 cells/mice, i.v. | Spinal cord injury (SCI) | Mice | Mammana et al. (127) |
| GMSC | Caffeic acid‐based bioconjugated hydrogel (CBGH) | n/a | SCI (hemitransection model) | Rat | Subbarayan et al. (128) |